Prognostic Significance of CT-Determined Sarcopenia in Patients with Small-Cell Lung Cancer

被引:193
作者
Kim, Eun Young [1 ]
Kim, Young Saing [2 ]
Park, Inkeun [2 ]
Ahn, Hee Kyung [2 ]
Cho, Eun Kyung [2 ]
Jeong, Yu Mi [1 ]
机构
[1] Gachon Univ, Gil Hosp, Dept Radiol, Inchon 405760, South Korea
[2] Gachon Univ, Gil Hosp, Dept Internal Med, Div Hematol & Oncol, Inchon 405760, South Korea
关键词
Sarcopenia; Skeletal muscle; Prognosis; Small-cell lung cancer; Tomography; X-ray computed; BODY-COMPOSITION; PREVALENCE; CHEMOTHERAPY; OBESITY; INDEX;
D O I
10.1097/JTO.0000000000000690
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: The primary objective of this study was to determine the prognostic significance of computed tomography (CT)-determined sarcopenia in small-cell lung cancer (SCLC) patients. Methods: This retrospective study consisted of a total of 149 consecutive SCLC patients. The cross-sectional area of muscle at the level of the third lumbar vertebra (L3) was measured using baseline CT images. Sarcopenia was defined as a L3 muscle index of less than 55 cm(2)/m(2) for men and of less than 39 cm(2)/m(2) for women as proposed by international consensus of cancer cachexia. In addition, Korean-specific cutoffs for sarcopenia was also applied (49 cm(2)/m(2) for men and 31 cm(2)/m(2) for women). Overall survival (OS) and clinical characteristics of patients with or without sarcopenia were compared. Results: Mean patient age was 68.6 9.5 years. Most were male (85.3%) and 67.8% had extensive disease at time of diagnosis. Sarcopenia was present in 118 patients (79.2%) and was significantly related to an advanced age (p = 0.028), male sex (p < 0.001), lower body mass index (p < 0.001), and poor performance status (p = 0.049). Sarcopenic patients had shorter OS than nonsarcopenic patients (median: 8.6 months versus 16.8 months; p = 0.031). Multivariable analysis revealed that sarcopenia was an independent prognostic factor of poor survival (hazards ratio: 1.68; 95% confidence interval: 1.04-2.72; p = 0.034), along with extensive stage (p < 0.001), supportive care only (p < 0.001), and an elevated lactate dehydrogenase level (p = 0.020). Using Korean sarcopenia cutoffs, sarcopenic patients were also found to have poorer OS than nonsarcopenic patients, however, the survival difference was not statistically significant (median: 8.4 months versus 12.7 months; p = 0.144 by the log-rank test). Conclusions: Sarcopenia as determined by CT could be used to predict prognosis in patients with SCLC. Optimum reference values to predict cancer-specific outcomes should be tailored by further studies.
引用
收藏
页码:1795 / 1799
页数:5
相关论文
共 23 条
[1]   Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis [J].
Baracos, Vickie E. ;
Reiman, Tony ;
Mourtzakis, Marina ;
Gioulbasanis, Ioannis ;
Antoun, Sami .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2010, 91 (04) :1133S-1137S
[2]   Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies [J].
Barba, C ;
Cavalli-Sforza, T ;
Cutter, J ;
Darnton-Hill, I ;
Deurenberg, P ;
Deurenberg-Yap, M ;
Gill, T ;
James, P ;
Ko, G ;
Miu, AH ;
Kosulwat, V ;
Kumanyika, S ;
Kurpad, A ;
Mascie-Taylor, N ;
Moon, HK ;
Nishida, C ;
Noor, MI ;
Reddy, KS ;
Rush, E ;
Schultz, JT ;
Seidell, J ;
Stevens, J ;
Swinburn, B ;
Tan, K ;
Weisell, R ;
Wu, ZS ;
Yajnik, CS ;
Yoshiike, N ;
Zimmet, P .
LANCET, 2004, 363 (9403) :157-163
[3]  
Baumgartner RN, 2000, ANN NY ACAD SCI, V904, P437
[4]   The assessment and impact of sarcopenia in lung cancer: a systematic literature review [J].
Collins, Jemima ;
Noble, Simon ;
Chester, John ;
Coles, Bernadette ;
Byrne, Anthony .
BMJ OPEN, 2014, 4 (01)
[5]   Definition and classification of cancer cachexia: an international consensus [J].
Fearon, Kenneth ;
Strasser, Florian ;
Anker, Stefan D. ;
Bosaeus, Ingvar ;
Bruera, Eduardo ;
Fainsinger, Robin L. ;
Jatoi, Aminah ;
Loprinzi, Charles ;
MacDonald, Neil ;
Mantovani, Giovanni ;
Davis, Mellar ;
Muscaritoli, Maurizio ;
Ottery, Faith ;
Radbruch, Lukas ;
Ravasco, Paula ;
Walsh, Declan ;
Wilcock, Andrew ;
Kaasa, Stein ;
Baracos, Vickie E. .
LANCET ONCOLOGY, 2011, 12 (05) :489-495
[6]   Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Frueh, M. ;
De Ruysscher, D. ;
Popat, S. ;
Crino, L. ;
Peters, S. ;
Felip, E. .
ANNALS OF ONCOLOGY, 2013, 24 :99-105
[7]   Sarcopenia as a Prognostic Biomarker of Advanced Urothelial Carcinoma [J].
Fukushima, Hiroshi ;
Yokoyama, Minato ;
Nakanishi, Yasukazu ;
Tobisu, Ken-ichi ;
Koga, Fumitaka .
PLOS ONE, 2015, 10 (01)
[8]   Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database [J].
Govindan, Ramaswamy ;
Page, Nathan ;
Morgensztern, Daniel ;
Read, William ;
Tierney, Ryan ;
Vlahiotis, Anna ;
Spitznagel, Edward L. ;
Piccirillo, Jay .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (28) :4539-4544
[9]   Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma [J].
Harimoto, N. ;
Shirabe, K. ;
Yamashita, Y. -I. ;
Ikegami, T. ;
Yoshizumi, T. ;
Soejima, Y. ;
Ikeda, T. ;
Maehara, Y. ;
Nishie, A. ;
Yamanaka, T. .
BRITISH JOURNAL OF SURGERY, 2013, 100 (11) :1523-1530
[10]   Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients [J].
Huillard, O. ;
Mir, O. ;
Peyromaure, M. ;
Tlemsani, C. ;
Giroux, J. ;
Boudou-Rouquette, P. ;
Ropert, S. ;
Delongchamps, N. Barry ;
Zerbib, M. ;
Goldwasser, F. .
BRITISH JOURNAL OF CANCER, 2013, 108 (05) :1034-1041